タナカ ジユンジ
TANAKA Junji
田中 淳司 所属 その他 その他 職種 非常勤嘱託 |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT. |
掲載誌名 | 正式名:Bone marrow transplantation 略 称:Bone Marrow Transplant ISSNコード:(1476-5365)0268-3369(Linking) |
掲載区分 | 国外 |
巻・号・頁 | 51(1),pp.43-50 |
著者・共著者 | Nishiwaki S†, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, Onishi Y, Takahashi S, Uchida N, Eto T, Nakamae H, Yujiri T, Mori S, Nagamura-Inoue T, Suzuki R, Atsuta Y, Tanaka J |
担当区分 | 最終著者 |
発行年月 | 2016/01 |
概要 | To assess the impact of minimal residual disease (MRD) and tyrosine kinase inhibitor (TKI) administration on allogeneic hematopoietic cell transplantation (allo-HCT) for Ph-positive ALL (Ph+ALL), we retrospectively analyzed data from a registry database for 432 adult Ph+ALL patients in first CR (CR1) who received pre-transplant TKI administration. Negative MRD (MRD(-)) at allo-HCT was achieved in 277 patients. OS in patients transplanted in MRD(-) was significantly better than that in patients transplanted in MRD(+) (MRD(-): 67% vs MRD(+): 55% at 4 years; P=0.001). MRD(-) at allo-HCT was a significant risk factor for survival along with age at allo-HCT in multivariate analyses. Incidence of relapse in patients transplanted in MRD(-) was significantly lower than that in patients transplanted in MRD(+) (MRD(-): 19% vs MRD(+): 29% at 4 years; P=0.006). In multivariate analyses, MRD(+) at allo-HCT was a significant risk factor for relapse. A post-transplant TKI was administered to 103 patients. In subanalyses regarding the effect of post-transplant TKI administration, post-transplant TKI administration was a significant risk factor for relapse in multivariate analyses (P<0.0001). MRD status at allo-HCT is one of the most important predictive factors for Ph+ALL patients transplanted in CR1. |
DOI | 10.1038/bmt.2015.217 |
PMID | 26389833 |